Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib) - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35302767/
Bruton's tyrosine kinase (BTK), a Tec family tyrosine kinase, is critical in immune pathways as an essential intracellular signaling element, participating in both adaptive and immune responses. Currently approved BTK...
Conclusion/Relevance: These compounds have exhibited potent and durable inhibition of BTK, in vivo efficacy in rodent arthritis models, and clinical efficacy in canine pemphigus foliaceus. Compound 11 has completed phase 1 trials as a topical agent, and 12 is in phase 3 trials for pemphigus vulgaris and immune thrombocytopenia
Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35303070/
Bruton tyrosine kinase (BTK) inhibitor is an established treatment for relapsed/refractory mantle cell lymphoma (R/R MCL). Zanubrutinib, a highly selective BTK inhibitor, is approved for patients with MCL who have...
Relevance: We report the long-term safety and efficacy results from the multicenter, open-label, phase 2 registration trial of zanubrutinib.
The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35247800/
doi: 10.1016/j.thromres.2022.02.020. 1 Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands. 2 Department of Internal Medicine, Catharina Hospital, Eindhoven, the Netherlands. 3 Department of Biochemistry,...
Conclusion: Treatment of patients with haematological disorders with the Btk inhibitor ibrutinib reduces in vitro platelet deposition, thrombus size and contraction on human atherosclerotic plaque around a stenosis when compared to patients not receiving ibrutinib.
-
Alireza Mirmiran4yrThank you very much, Naveed Saleh.
-
Leukemia and Lymphoma Connect4yrKey Points • Source: Thrombus Research • Conclusions. “Treatment of patients with haematological disorders with the Btk inhibitor ibrutinib reduces in vitro platelet deposition, thrombus size and contraction on human atherosclerotic plaque around a Show More
new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas
Research Article | Manit Munshi, Xia Liu, Amanda Kofides, Nicholas Tsakmaklis, Maria Luisa Guerrera, Zachary R Hunter, Maria Lia Palomba, Kimon V. Argyropoulos, Christopher J Patterson, Alexa G Canning, Kirsten...
Conclusion: Taken together, our findings show that SYK is activated by HCK in MYD88Mut B-cell lymphomas cells; broaden the pro-survival signaling generated by aberrant HCK expression in response to MYD88Mut; and help define HCK as an important therapeutic target in MYD88Mut B-cell lymphomas.
Immunoglobulin substitution in patients with secondary antibody deficiency in chronic lymphocytic leukemia and multiple myeloma: a representative analysis of guideline adherence and infections - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35257229/
doi: 10.1007/s00520-022-06920-y. Online ahead of print. 1 Internal Medicine, Hematology and Medical Oncology, Kaiserslautern, Finkenhain 8, D-67661, Kaiserslautern, Germany. [email protected]. 2 MMF GmbH, Lindberghweg 132, D-48155, Münster, Germany. doi: 10.1007/s00520-022-06920-y....
Conclusions: Guideline adherence correlated with fewer and less severe infections but was low in patients with indication to IgRT. Risk factors for infection can be identified. Risk of severe infections was significantly lower in patients with IgRT